Gossamer Bio’s (GOSS) Buy Rating Reiterated at HC Wainwright

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $10.00 price objective on the stock.

Gossamer Bio Price Performance

Gossamer Bio stock opened at $0.92 on Thursday. The company’s fifty day moving average price is $0.86 and its 200 day moving average price is $0.90. Gossamer Bio has a 1 year low of $0.50 and a 1 year high of $1.60. The stock has a market capitalization of $208.15 million, a P/E ratio of -2.87 and a beta of 1.81. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. The firm had revenue of $9.48 million during the quarter, compared to analysts’ expectations of $4.52 million. As a group, equities research analysts anticipate that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Jacobs Levy Equity Management Inc. raised its holdings in shares of Gossamer Bio by 30.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock worth $1,862,000 after acquiring an additional 442,895 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Gossamer Bio by 24.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock worth $380,000 after acquiring an additional 74,920 shares during the period. GSA Capital Partners LLP purchased a new position in shares of Gossamer Bio during the 3rd quarter worth $67,000. US Bancorp DE purchased a new position in shares of Gossamer Bio during the 3rd quarter worth $39,000. Finally, Sequoia Financial Advisors LLC raised its holdings in shares of Gossamer Bio by 26.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock worth $117,000 after acquiring an additional 25,000 shares during the period. Hedge funds and other institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.